Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen Sells 15,000 Shares
Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $62.97, for a total transaction of $944,550.00. Following the sale, the executive vice president now owns 17,991 shares in the company, valued at $1,132,893.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Tandem Diabetes Care stock traded up $1.53 during mid-day trading on Tuesday, hitting $63.44. The company had a trading volume of 953,121 shares, compared to its average volume of 1,744,785. The stock has a market cap of $3.75 billion, a PE ratio of -24.88 and a beta of 0.33. Tandem Diabetes Care Inc has a 1 year low of $26.40 and a 1 year high of $74.81. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.21 and a current ratio of 2.53. The business has a fifty day moving average of $63.77.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.20. The company had revenue of $93.26 million for the quarter, compared to analyst estimates of $69.95 million. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The firm’s revenue was up 173.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.33) earnings per share. As a group, equities analysts expect that Tandem Diabetes Care Inc will post -0.65 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 53.3% in the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 160 shares during the period. Bremer Bank National Association acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at approximately $31,000. TRUE Private Wealth Advisors acquired a new stake in shares of Tandem Diabetes Care in the second quarter valued at approximately $33,000. James Investment Research Inc. boosted its holdings in shares of Tandem Diabetes Care by 15.9% in the second quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after acquiring an additional 180 shares during the period. Finally, Stephens Inc. AR acquired a new stake in shares of Tandem Diabetes Care in the second quarter valued at approximately $113,000. 79.75% of the stock is owned by institutional investors and hedge funds.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Story: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.